HomeABCL • NASDAQ
add
AbCellera Biologics Inc
Previous close
$3.59
Day range
$3.36 - $3.62
Year range
$1.89 - $6.52
Market cap
1.09B USD
Avg Volume
4.47M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 44.85M | 788.18% |
Operating expense | 23.34M | 8,713.28% |
Net income | -8.94M | 73.85% |
Net profit margin | -19.94 | 97.06% |
Earnings per share | -0.03 | 75.00% |
EBITDA | -22.46M | 13.76% |
Effective tax rate | 54.13% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 533.83M | -14.67% |
Total assets | 1.36B | -0.26% |
Total liabilities | 390.05M | 28.11% |
Total equity | 966.90M | — |
Shares outstanding | 303.16M | — |
Price to book | 1.11 | — |
Return on assets | -5.27% | — |
Return on capital | -6.45% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | -8.94M | 73.85% |
Cash from operations | -34.74M | -334.29% |
Cash from investing | 75.14M | 110.45% |
Cash from financing | 4.12M | -0.65% |
Net change in cash | 44.80M | 50.92% |
Free cash flow | -6.97M | 90.38% |
About
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. Wikipedia
CEO
Founded
2012
Headquarters
Website
Employees
562
